Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to -$10.2 million.

  • Vanda Pharmaceuticals' Change in Accured Expenses fell 207974.41% to -$10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 3558.47%. This contributed to the annual value of $1.7 million for FY2024, which is 11554.99% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Change in Accured Expenses is -$10.2 million, which was down 207974.41% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Change in Accured Expenses ranged from a high of $13.4 million in Q1 2022 and a low of -$10.8 million during Q1 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $306000.0 (2022), whereas its average is $647368.4.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Change in Accured Expenses surged by 487857.14% in 2022, and later crashed by 207974.41% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $2.2 million in 2021, then plummeted by 250.32% to -$3.3 million in 2022, then skyrocketed by 201.65% to $3.3 million in 2023, then crashed by 163.85% to -$2.1 million in 2024, then plummeted by 380.63% to -$10.2 million in 2025.
  • Its last three reported values are -$10.2 million in Q3 2025, $11.3 million for Q2 2025, and $5.6 million during Q1 2025.